Novartis acquires Kedalion Therapeutics and its ocular delivery platform

Article

The company intends to develop the AcuStream technology for potential use with its current and future front-of-eye therapies, which may include lifitegrast ophthalmic solution for the treatment of dry eye disease.

Novartis has purchased Kedalion Therapeutics and its AcuStream technology, the company announced on June 30.

The AcuStream platform is a preservative-free, electromechanical ocular delivery service with the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye, according to the company news release.

Novartis acquires Kedalion Therapeutics and its ocular delivery platform



Novartis currently intends to expand AcuStream for use with both future and existing front-of-eye therapies, including Xiidra (lifitegrast ophthalmic solution) 5%, which is used for the treatment of dry eye disease (DED).

Kedalion Therapeutics is a clinical-stage, venture-funded ophthalmic drug company based in California. The company announced the completion of its Series B funding—led by Novartis—in November 2021.

The funding included an exclusive option to acquire Kedalion and its AcuStream technology, according to the release.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders what she would like to see develop as both a researcher and a clinician in the dry eye space.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
© 2025 MJH Life Sciences

All rights reserved.